Real-world evidence of nivolumab monotherapy in advanced renal cell carcinoma from a multicenter retrospective cohort study by the Spanish Genitourinary Oncology Group

Ana Pertejo-Fernández; O. Fernández-Calvo; Urbano Anido; Juan Ruiz‐Bañobre

doi:10.1186/s12885-025-15264-9

November 28, 2025BMC CancerOpen Access

Real-world evidence of nivolumab monotherapy in advanced renal cell carcinoma from a multicenter retrospective cohort study by the Spanish Genitourinary Oncology Group

View Full Paper

Ask AI

Bookmark

Share

Key Points

Nivolumab demonstrates efficacy in advanced renal cell carcinoma, confirming clinical trial results.
Efficacy observed in a multicenter cohort of previously treated patients.
Assessment using real-world evidence data from clinical settings in Spain allows for broader insights.
Findings support nivolumab's role as a treatment option in practice, requiring ongoing evaluation.

Implication

Retrospective cohort study shows nivolumab maintains efficacy in clinical practice for advanced renal cell carcinoma.

Abstract

Consistent with previous clinical trials and RWE studies, our findings reinforce the efficacy of nivolumab in routine clinical practice for an unselected cohort of previously treated aRCC patients in Spain.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Pertejo-Fernández et al. (2025) studied this question.

synapsesocial.com/papers/692e3d8d6c9b3ab28c18771e https://doi.org/10.1186/s12885-025-15264-9

View Full Paper

Ask AI

Bookmark

Share

Real-world evidence of nivolumab monotherapy in advanced renal cell carcinoma from a multicenter retrospective cohort study by the Spanish Genitourinary Oncology Group

Key Points

Implication

Abstract

Discussion

Cite This Study

Real-world evidence of nivolumab monotherapy in advanced renal cell carcinoma from a multicenter retrospective cohort study by the Spanish Genitourinary Oncology Group

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading